Navigation Links
Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Date:1/7/2008

TAMPA, Fla., Jan. 7 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer.

Most recently, Dr. Keeffe served as Professor of Medicine, Chief of Hepatology and Co-Director of the Liver Transplant Program at Stanford University Medical Center. He is a past-president of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, and served as chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine. He is a Master of the American College of Physicians and a Fellow of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the Royal College of Physicians of Ireland.

"Romark's drug discovery research and ongoing clinical development programs offer the promise of new drugs that could change paradigms for treating viral hepatitis," said Dr. Keeffe. "I am excited to have the opportunity to contribute to the advancement of new therapies in this field."

Dr. Keeffe's research interests include antiviral therapy of chronic hepatitis B and C, use of hepatitis vaccines, and liver transplant selection criteria and outcomes. Throughout his career, he has been an active clinical investigator, with a major focus on novel treatment of chronic viral hepatitis and has published more than 500 papers, book chapters and miscellaneous publications. He lectures widely at national and international scientific meetings, and postgraduate courses.

"We are pleased that Dr. Keeffe has chosen to join our Company," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "His expertise in the fields of hepatology and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides for treating viral hepatitis and other digestive diseases."

About Romark Laboratories

Romark Laboratories, L.C. (http://www.romark.com) is a biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases. The Company is developing nitazoxanide for treating chronic hepatitis C and is developing other new thiazolides for treating viral diseases including chronic hepatitis B and C, and influenza.


'/>"/>
SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
5. ARUP Laboratories Releases ARUP Consult(R) 2.0
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. Stiefel Laboratories Appoints Two New Members to Board of Directors
8. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... algorithms targeted towards leveraging the years of diagnostic excellence by Mayo Clinic and ... The first product suite will be distributed through the Microsoft Azure platform and ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... leading company for the improvement of crop productivity and economics for the food, ... collaboration. The scope of the agreement includes the research and development of microbiome-based ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Fiberstar, ... food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used to ... and extend real tomato in sauces, condiments and spreads. Today, more than ever, consumers ...
(Date:7/25/2017)... Canaan, CT (PRWEB) , ... July 25, 2017 ... ... sustainable products that enhance the microbiome and improve efficiency of livestock farming while ... announced that it has licensed additional intellectual property from Cornell University. , ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):